PRDM9 and cancer: On the other hand, some histone methyltransferase drugs, BET inhibitors and non-coding RNAs can also trigger TIL changes regulated by IFN-γ that is responsible for PD-L1 expression on immune system cells and cancer cells which reflects the mechanisms of acquired resistance [99, 112].